(Q24202499)

2

0 references

author name string

Tine LM de Backer

1

0 references

Philippe Lehert

3

0 references

Luc Van Bortel

Cochrane Database of Systematic Reviews

4

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Lipid-lowering for peripheral arterial disease of the lower limb

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Management of peripheral arterial disease in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Intermittent claudication and rest pain: Physiologic concepts and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

The prevalence of peripheral arterial disease in a defined population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Buflomedil for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Oral vasoactive medication in intermittent claudication: utile or futile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Naftidrofuryl: a review of its use in the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Meta-analysis of continuous outcome data from individual patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Vitamin E for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Exercise for intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Pharmacological management of intermittent claudication: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Peripheral arterial disease: identification and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Prostanoids for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Cilostazol for peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Omega-3 fatty acids for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB4

Effects of naftidrofuryl in patients with intermittent claudication

21 January 2018

1 reference

12 December 2020

A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication

1 reference

12 December 2020

Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration

1 reference

12 December 2020

Clinical effectiveness of naftidrofuryl in intermittent claudication

1 reference

12 December 2020

The effect of naftidrofuryl on intermittent claudication: a meta-analysis

1 reference

12 December 2020

An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl

1 reference

12 December 2020

Surgical treatment of peripheral circulation disorders

1 reference

12 December 2020

Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).

1 reference

12 December 2020

Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease

1 reference

12 December 2020

Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study

1 reference

12 December 2020

Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study

1 reference

12 December 2020

A primary care approach to the patient with claudication

1 reference

12 December 2020

A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).

1 reference

12 December 2020

The relation between peripheral arterial occlusive disease and cardiovascular diseases in elderly population: a cross-section study in Wanshoulu area, Beijing

1 reference

12 December 2020

Naftidrofuryl in quality of life (NIQOL). A Belgian study.

1 reference

12 December 2020

The fading of reported effectiveness. A meta-analysis of randomised controlled trials

1 reference

12 December 2020

Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg

1 reference

12 December 2020

Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials

1 reference

12 December 2020

Naftidrofuryl for intermittent claudication

1 reference

12 December 2020

Naftidrofuryl for intermittent claudication: a double-blind controlled trial

1 reference

12 December 2020

[Epidemiology and prognosis of peripheral obliterative arteriopathy].

1 reference

12 December 2020